Sign in or create an account to add this stock to your watchlist.
About Amicus Therapeutics (NASDAQ:FOLD)
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:FOLD
CUSIP03152W10
Phone609-662-2000
Debt
Debt-to-Equity Ratio0.32
Current Ratio4.21
Quick Ratio4.15
Price-To-Earnings
Trailing P/E Ratio-5.41
Forward P/E Ratio-12.53
P/E GrowthN/A
Sales & Book Value
Annual Sales$36.93 million
Price / Sales80.58
Cash FlowN/A
Price / CashN/A
Book Value$2.77 per share
Price / Book5.70
Profitability
EPS (Most Recent Fiscal Year)($2.92)
Net Income$-284,000,000.00
Net Margins-563.98%
Return on Equity-60.09%
Return on Assets-29.90%
Miscellaneous
Employees325
Outstanding Shares188,470,000
Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions
What is Amicus Therapeutics' stock symbol?
Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."
How were Amicus Therapeutics' earnings last quarter?
Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.36) by $0.08. The biopharmaceutical company had revenue of $16.70 million for the quarter, compared to analysts' expectations of $16.78 million. Amicus Therapeutics had a negative return on equity of 60.09% and a negative net margin of 563.98%. View Amicus Therapeutics' Earnings History.
When is Amicus Therapeutics' next earnings date?
What price target have analysts set for FOLD?
7 equities research analysts have issued twelve-month target prices for Amicus Therapeutics' stock. Their forecasts range from $15.00 to $24.00. On average, they expect Amicus Therapeutics' stock price to reach $19.50 in the next twelve months. View Analyst Ratings for Amicus Therapeutics.
Are investors shorting Amicus Therapeutics?
Amicus Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 29,349,145 shares, an increase of 0.6% from the April 30th total of 29,160,247 shares. Based on an average trading volume of 2,613,137 shares, the short-interest ratio is presently 11.2 days. Approximately 16.0% of the company's stock are short sold.
Who are some of Amicus Therapeutics' key competitors?
Some companies that are related to Amicus Therapeutics include Perrigo (PRGO), BeiGene (BGNE), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), Dr. Reddy's Laboratories (RDY) and Taro Pharmaceutical Industries (TARO).
Who are Amicus Therapeutics' key executives?
Amicus Therapeutics' management team includes the folowing people:
- Mr. John F. Crowley, Chairman and Chief Exec. Officer (Age 51)
- Mr. Bradley L. Campbell, Pres and Chief Operating Officer (Age 42)
- Mr. William D. Baird III, Chief Financial Officer (Age 46)
- Dr. Hung Do Ph.D., Chief Science Officer (Age 50)
- Dr. Jay A. Barth M.D., Chief Medical Officer (Age 54)
Has Amicus Therapeutics been receiving favorable news coverage?
Headlines about FOLD stock have trended somewhat positive this week, according to Accern. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amicus Therapeutics earned a news sentiment score of 0.09 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.41 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Amicus Therapeutics' major shareholders?
Amicus Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.03%), Redmile Group LLC (5.70%), Palo Alto Investors LP (3.26%), Franklin Resources Inc. (2.00%), Farallon Capital Management LLC (1.85%) and Victory Capital Management Inc. (1.63%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.
Which institutional investors are selling Amicus Therapeutics stock?
FOLD stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Highland Capital Management LP, Royal Bank of Canada, Prudential Financial Inc., Copernicus Capital Management LLC, Candriam Luxembourg S.C.A., Seven Eight Capital LP and Russell Investments Group Ltd.. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Margaret G Mcglynn, Michael Raab and William D Baird III. View Insider Buying and Selling for Amicus Therapeutics.
Which institutional investors are buying Amicus Therapeutics stock?
FOLD stock was acquired by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, BlackRock Inc., Sphera Funds Management LTD., Redmile Group LLC, Farallon Capital Management LLC, Victory Capital Management Inc., Loomis Sayles & Co. L P and Delek Group Ltd.. Company insiders that have bought Amicus Therapeutics stock in the last two years include Ellen Rosenberg, John F Crowley, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.
How do I buy shares of Amicus Therapeutics?
Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amicus Therapeutics' stock price today?
One share of FOLD stock can currently be purchased for approximately $15.79.
How big of a company is Amicus Therapeutics?
Amicus Therapeutics has a market capitalization of $2.86 billion and generates $36.93 million in revenue each year. The biopharmaceutical company earns $-284,000,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Amicus Therapeutics employs 325 workers across the globe.
How can I contact Amicus Therapeutics?
Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]
MarketBeat Community Rating for Amicus Therapeutics (FOLD)
MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote "Outperform" if you believe FOLD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOLD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Amicus Therapeutics (NASDAQ:FOLD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Amicus Therapeutics in the last 12 months. Their average twelve-month price target is $19.50, suggesting that the stock has a possible upside of 23.50%. The high price target for FOLD is $24.00 and the low price target for FOLD is $15.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.86 | 2.86 | 2.86 | 2.86 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $19.50 | $19.50 | $19.50 | $18.0714 |
| Price Target Upside: | 23.50% upside | 17.75% upside | 17.75% upside | 13.09% upside |
Amicus Therapeutics (NASDAQ:FOLD) Consensus Price Target History
Amicus Therapeutics (NASDAQ:FOLD) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Amicus Therapeutics (NASDAQ:FOLD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Amicus Therapeutics (NASDAQ FOLD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.90%
Amicus Therapeutics (NASDAQ FOLD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/16/2018 | Hung Do | Insider | Sell | 25,000 | $15.00 | $375,000.00 | 421,771 |  |
| 5/16/2018 | Margaret G Mcglynn | Director | Sell | 10,000 | $16.00 | $160,000.00 | 25,814 | |
| 5/14/2018 | Jay Barth | Insider | Sell | 5,000 | $14.04 | $70,200.00 | 90,409 | |
| 4/17/2018 | Hung Do | Insider | Sell | 50,000 | $15.00 | $750,000.00 | 446,771 | |
| 4/16/2018 | Michael Raab | Director | Sell | 5,000 | $14.41 | $72,050.00 | 10,814 | |
| 4/12/2018 | Jay Barth | Insider | Sell | 5,000 | $14.72 | $73,600.00 | 90,409 | |
| 4/2/2018 | Kurt J Andrews | SVP | Sell | 5,000 | $14.27 | $71,350.00 | 45,469 | |
| 4/2/2018 | William D Baird III | CFO | Sell | 10,000 | $14.26 | $142,600.00 | 127,662 | |
| 3/12/2018 | Jay Barth | Insider | Sell | 5,000 | $15.05 | $75,250.00 | 90,409 | |
| 3/9/2018 | Daphne Quimi | SVP | Sell | 8,750 | $15.00 | $131,250.00 | 73,082 | |
| 3/5/2018 | Perceptive Advisors Llc | Major Shareholder | Buy | 335,827 | $13.56 | $4,553,814.12 | | |
| 3/1/2018 | Daphne Quimi | SVP | Sell | 8,149 | $14.06 | $114,574.94 | 72,481 | |
| 3/1/2018 | Life Sciences Maste Perceptive | Major Shareholder | Buy | 100,000 | $13.69 | $1,369,000.00 | | |
| 1/23/2018 | Jay Barth | Insider | Sell | 20,000 | $16.80 | $336,000.00 | 105,409 | |
| 1/22/2018 | Bradley L Campbell | COO | Sell | 32,500 | $15.92 | $517,400.00 | 186,600 | |
| 1/2/2018 | Daphne Quimi | SVP | Sell | 8,000 | $14.72 | $117,760.00 | 62,676 | |
| 1/2/2018 | Donald J Hayden Jr | Director | Sell | 20,000 | $15.00 | $300,000.00 | 25,814 | |
| 1/2/2018 | Jay Barth | Insider | Sell | 5,000 | $14.71 | $73,550.00 | 69,184 | |
| 1/2/2018 | William D Baird III | CFO | Sell | 10,000 | $14.72 | $147,200.00 | 105,121 | |
| 12/29/2017 | John F Crowley | CEO | Sell | 18,970 | $14.75 | $279,807.50 | | |
| 12/29/2017 | John F Crowley | CEO | Sell | 5,920 | $14.75 | $87,320.00 | 341,051 | |
| 12/21/2017 | John F Crowley | CEO | Sell | 65,581 | $13.51 | $885,999.31 | 393,076 | |
| 12/11/2017 | John F Crowley | CEO | Sell | 12,206 | $13.52 | $165,025.12 | 340,207 | |
| 12/4/2017 | John F Crowley | CEO | Sell | 47,213 | $13.61 | $642,568.93 | 375,214 | |
| 12/1/2017 | Jay Barth | Insider | Sell | 5,000 | $13.59 | $67,950.00 | 69,184 | |
| 10/18/2017 | John F Crowley | CEO | Sell | 71,735 | $14.75 | $1,058,091.25 | 380,723 | |
| 10/16/2017 | John F Crowley | CEO | Sell | 449,295 | $14.33 | $6,438,397.35 | 380,723 | |
| 10/12/2017 | Daphne Quimi | SVP | Sell | 7,000 | $14.25 | $99,750.00 | | |
| 10/12/2017 | Hung Do | Insider | Sell | 50,194 | $14.25 | $715,264.50 | | |
| 10/12/2017 | Michael Raab | Director | Sell | 10,000 | $14.25 | $142,500.00 | | |
| 10/12/2017 | William D Baird III | CFO | Sell | 40,000 | $14.25 | $570,000.00 | | |
| 9/26/2017 | John F Crowley | CEO | Buy | 1,395 | $14.36 | $20,032.20 | 328,001 | |
| 7/13/2017 | Life Sciences Maste Perceptive | Major Shareholder | Buy | 1,500,000 | $12.25 | $18,375,000.00 | | |
| 6/19/2017 | Jay Barth | Insider | Sell | 30,000 | $10.00 | $300,000.00 | 64,184 | |
| 5/19/2017 | Hung Do | Insider | Sell | 29,914 | $8.00 | $239,312.00 | 474,438 | |
| 3/2/2017 | Bradley L Campbell | COO | Sell | 49,050 | $8.00 | $392,400.00 | 127,475 | |
| 1/13/2017 | Hung Do | Insider | Sell | 25,000 | $6.00 | $150,000.00 | 559,266 | |
| 12/30/2016 | Perceptive Advisors Llc | Major Shareholder | Buy | 94,750 | $4.96 | $469,960.00 | | |
| 12/29/2016 | Perceptive Advisors Llc | Major Shareholder | Buy | 142,125 | $4.87 | $692,148.75 | | |
| 12/23/2016 | Perceptive Advisors Llc | Major Shareholder | Buy | 85,275 | $4.81 | $410,172.75 | | |
| 12/22/2016 | Perceptive Advisors Llc | Major Shareholder | Buy | 189,500 | $4.51 | $854,645.00 | | |
| 11/9/2016 | Daphne Quimi | SVP | Sell | 8,546 | $8.00 | $68,368.00 | 24,189 | |
| 11/1/2016 | Hung Do | Insider | Sell | 25,000 | $7.00 | $175,000.00 | 533,453 | |
| 10/3/2016 | Hung Do | Insider | Sell | 25,000 | $7.25 | $181,250.00 | 558,453 | |
| 9/20/2016 | William D Baird III | CFO | Sell | 20,500 | $8.00 | $164,000.00 | 56,450 | |
| 9/6/2016 | Hung Do | Insider | Sell | 25,000 | $7.00 | $175,000.00 | 583,453 | |
| 8/25/2016 | Perceptive Advisors Llc | Insider | Sell | 1,100,000 | $6.81 | $7,491,000.00 | | |
| 8/4/2016 | Jay Barth | Insider | Sell | 10,458 | $7.00 | $73,206.00 | 15,000 | |
| 7/27/2016 | Jay Barth | Insider | Sell | 20,916 | $7.00 | $146,412.00 | 25,458 | |
| 6/2/2016 | Ellen Rosenberg | General Counsel | Buy | 15,000 | $7.67 | $115,050.00 | | |
| 11/10/2015 | Margaret G Mcglynn | Director | Buy | 10,000 | $10.27 | $102,700.00 | 10,000 | |
| 10/7/2015 | Perceptive Advisors Llc | Major Shareholder | Buy | 50,000 | $6.27 | $313,500.00 | | |
| 10/6/2015 | Perceptive Advisors Llc | Major Shareholder | Buy | 750,000 | $6.71 | $5,032,500.00 | | |
| 10/1/2015 | Kenneth Peist | VP | Sell | 10,000 | $13.14 | $131,400.00 | 3,187 | |
| 9/21/2015 | Bradley L. Campbell | COO | Sell | 13,001 | $16.78 | $218,156.78 | 156,575 | |
| 9/21/2015 | William D. Baird III | CFO | Sell | 15,236 | $16.78 | $255,660.08 | 56,575 | |
| 9/15/2015 | Hung Do | Insider | Sell | 25,000 | $17.75 | $443,750.00 | 720,953 | |
| 9/14/2015 | Daphne Quimi | VP | Sell | 2,500 | $18.08 | $45,200.00 | 5,688 | |
| 7/16/2015 | John F Crowley | CEO | Sell | 16,025 | $16.00 | $256,400.00 | | |
| 7/14/2015 | John F Crowley | CEO | Sell | 142,250 | $15.03 | $2,138,017.50 | | |
| 7/13/2015 | Glenn Sblendorio | Director | Sell | 10,000 | $15.00 | $150,000.00 | | |
| 7/13/2015 | John F Crowley | CEO | Sell | 7,750 | $15.01 | $116,327.50 | | |
| 7/13/2015 | Ken Valenzano | SVP | Sell | 15,000 | $15.00 | $225,000.00 | | |
| 7/8/2015 | Dipal Doshi | SVP | Sell | 6,250 | $13.87 | $86,687.50 | | |
| 7/1/2015 | Jayne Gershkowitz | SVP | Sell | 10,649 | $13.97 | $148,766.53 | | |
| 7/1/2015 | Kenneth Peist | VP | Sell | 10,000 | $13.98 | $139,800.00 | | |
| 6/23/2015 | Donald J Hayden Jr | Director | Sell | 55,000 | $14.01 | $770,550.00 | | |
| 6/22/2015 | Jeff Castelli | SVP | Sell | 18,981 | $13.94 | $264,595.14 | | |
| 6/19/2015 | Bradley L Campbell | COO | Sell | 13,000 | $13.26 | $172,380.00 | | |
| 6/19/2015 | Enrique Dilone | SVP | Sell | 14,045 | $13.26 | $186,236.70 | | |
| 6/19/2015 | William D Baird III | CFO | Sell | 15,235 | $13.26 | $202,016.10 | | |
| 6/15/2015 | Jeff Castelli | SVP | Sell | 7,377 | $14.17 | $104,532.09 | | |
| 6/15/2015 | Julie Yu | VP | Sell | 8,195 | $14.17 | $116,123.15 | | |
| 6/8/2015 | Jeff Castelli | SVP | Sell | 17,312 | $12.87 | $222,805.44 | | |
| 6/8/2015 | John F Crowley | CEO | Sell | 55,000 | $13.01 | $715,550.00 | | |
| 5/11/2015 | Jeff Castelli | SVP | Sell | 10,000 | $10.84 | $108,400.00 | | |
| 5/11/2015 | Kenneth Peist | VP | Sell | 12,500 | $10.84 | $135,500.00 | | |
| 5/11/2015 | William D Baird III | CFO | Sell | 24,800 | $10.84 | $268,832.00 | | |
| 4/15/2015 | Glenn Sblendorio | Director | Sell | 20,000 | $12.50 | $250,000.00 | | |
| 4/15/2015 | Ken Valenzano | VP | Sell | 5,000 | $12.50 | $62,500.00 | | |
| 4/10/2015 | John F Crowley | CEO | Sell | 11,678 | $12.00 | $140,136.00 | | |
| 4/1/2015 | Jeff Castelli | VP | Sell | 9,489 | $10.69 | $101,437.41 | | |
| 1/5/2015 | Jeff Castelli | VP | Sell | 4,667 | $9.00 | $42,003.00 | | |
| 12/4/2014 | John F Crowley | CEO | Sell | 89,000 | $8.36 | $744,040.00 | | |
| 11/25/2014 | Bradley L Campbell | COO | Sell | 7,250 | $8.00 | $58,000.00 | | |
| 11/25/2014 | Jeff Castelli | VP | Sell | 8,103 | $8.00 | $64,824.00 | | |
| 11/25/2014 | William D Baird III | CFO | Sell | 10,000 | $8.00 | $80,000.00 | | |
| 11/19/2014 | Perceptive Advisors Llc | Major Shareholder | Buy | 2,100,000 | $6.50 | $13,650,000.00 | | |
| 10/27/2014 | Plc Glaxosmithkline | Major Shareholder | Sell | 11,315,825 | $5.29 | $59,860,714.25 | | |
| 10/3/2014 | Jeff Castelli | VP | Sell | 8,552 | $7.00 | $59,864.00 | | |
| 10/3/2014 | William D Baird III | CFO | Sell | 10,000 | $7.00 | $70,000.00 | | |
| 10/2/2014 | Julie Yu | VP | Sell | 4,759 | $5.99 | $28,506.41 | | |
| 9/29/2014 | Daphne Quimi | VP | Sell | 10,738 | $6.10 | $65,501.80 | | |
| 9/29/2014 | William D Baird III | CFO | Sell | 25,311 | $6.09 | $154,143.99 | | |
| 8/27/2014 | Glenn Sblendorio | Director | Sell | 10,000 | $6.50 | $65,000.00 | | |
| 8/27/2014 | Jayne Gershkowitz | VP | Sell | 5,000 | $7.00 | $35,000.00 | | |
| 8/25/2014 | Bradley L Campbell | COO | Sell | 7,000 | $6.00 | $42,000.00 | | |
| 8/25/2014 | Jayne Gershkowitz | VP | Sell | 5,000 | $6.00 | $30,000.00 | | |
| 8/20/2014 | Bradley L Campbell | COO | Sell | 18,750 | $5.40 | $101,250.00 | | |
| 8/20/2014 | Enrique Dilone | VP | Sell | 12,810 | $5.40 | $69,174.00 | | |
| 6/30/2014 | Perceptive Advisors Llc | Major Shareholder | Buy | 4,000,000 | $3.50 | $14,000,000.00 | | |
| 11/20/2013 | Plc Glaxosmithkline | major shareholder | Buy | 1,500,000 | $2.00 | $3,000,000.00 | | |
| 3/15/2013 | Sol J Barer | Director | Buy | 25,000 | $3.40 | $85,000.00 | | |
| 11/13/2012 | Joan Winterbottom | SVP | Buy | 1,665 | $4.54 | $7,559.10 | | |
(Data available from 1/1/2013 forward)
Amicus Therapeutics (NASDAQ FOLD) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Amicus Acquires Scioderm, Adds Drug for Rare Skin Disorder to Pipeline
www.thestreet.com - May 25 at 5:49 PM |
 | Free Daily Technical Summary Reports on Amicus Therapeutics and Three Other Biotech Stocks
finance.yahoo.com - May 23 at 8:02 AM |
 | Is Amicus On The Verge Of A Breakout?
seekingalpha.com - May 20 at 8:26 AM |
 | Amicus Therapeutics (FOLD) Upgraded to Strong-Buy by BidaskClub
www.americanbankingnews.com - May 19 at 1:00 PM |
| Amicus Therapeutics (FOLD) Director Sells $160,000.00 in Stock
www.americanbankingnews.com - May 18 at 8:32 PM |
 | Interesting FOLD Put And Call Options For September 21st
www.nasdaq.com - May 18 at 5:42 PM |
| $18.92 Million in Sales Expected for Amicus Therapeutics (FOLD) This Quarter
www.americanbankingnews.com - May 18 at 2:18 AM |
| Insider Selling: Amicus Therapeutics (FOLD) Insider Sells 25,000 Shares of Stock
www.americanbankingnews.com - May 16 at 7:50 PM |
| Amicus Therapeutics (FOLD) Expected to Post Earnings of -$0.33 Per Share
www.americanbankingnews.com - May 16 at 5:16 PM |
| Amicus Therapeutics (FOLD) Insider Sells $70,200.00 in Stock
www.americanbankingnews.com - May 15 at 10:10 PM |
| Edited Transcript of FOLD earnings conference call or presentation 8-May-18 12:30pm GMT
finance.yahoo.com - May 12 at 8:00 AM |
| Amicus Therapeutics (FOLD) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - May 10 at 10:52 PM |
| Leerink Swann Equities Analysts Raise Earnings Estimates for Amicus Therapeutics (FOLD)
www.americanbankingnews.com - May 10 at 6:54 AM |
| Amicus Therapeutics (FOLD) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 10 at 3:32 AM |
| Amicus Therapeutics (FOLD) Announces Earnings Results, Beats Expectations By $0.08 EPS
www.americanbankingnews.com - May 9 at 8:34 PM |
| Amicus Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 9 at 8:12 AM |
| Traders Purchase High Volume of Call Options on Amicus Therapeutics (FOLD)
www.americanbankingnews.com - May 9 at 6:49 AM |
| Amicus Therapeutics down 3% on Q1 results
seekingalpha.com - May 8 at 5:46 PM |
| Amicus Therapeutics' (FOLD) CEO John Crowley on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:46 PM |
| When Can We Expect A Profit From Amicus Therapeutics Inc (NASDAQ:FOLD)?
finance.yahoo.com - May 8 at 5:46 PM |
| Amicus Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 5:46 PM |
| Amicus Therapeutics' (FOLD) "Buy" Rating Reaffirmed at Cowen
www.americanbankingnews.com - May 8 at 4:40 PM |
| Amicus Therapeutics beats by $0.08, misses on revenue
seekingalpha.com - May 8 at 8:12 AM |
| Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates
finance.yahoo.com - May 8 at 8:12 AM |
| Amicus Therapeutics (FOLD) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - May 5 at 12:12 AM |
| ValuEngine Upgrades Amicus Therapeutics (FOLD) to Strong-Buy
www.americanbankingnews.com - May 4 at 12:52 AM |
| Zacks Investment Research Downgrades Amicus Therapeutics (FOLD) to Sell
www.americanbankingnews.com - May 3 at 12:14 AM |
| Amicus Therapeutics (FOLD) Expected to Announce Quarterly Sales of $16.78 Million
www.americanbankingnews.com - May 1 at 4:12 AM |
| Analyzing the Market Potential for Amicus’s Galafold
finance.yahoo.com - April 30 at 5:29 PM |
| Exploring Amicus Therapeutics’ Promising Research Pipeline
finance.yahoo.com - April 30 at 5:29 PM |
| Analyzing the Financial Performance of Amicus Therapeutics
finance.yahoo.com - April 30 at 5:29 PM |
| Amicus Therapeutics (FOLD) to Release Earnings on Monday
www.americanbankingnews.com - April 30 at 7:49 AM |
| Brokerages Anticipate Amicus Therapeutics (FOLD) to Post -$0.36 Earnings Per Share
www.americanbankingnews.com - April 29 at 5:16 AM |
 | Amicus Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018
feeds.benzinga.com - April 26 at 7:57 AM |
| Traders Buy High Volume of Amicus Therapeutics Call Options (FOLD)
www.americanbankingnews.com - April 25 at 7:36 AM |
| Amicus Therapeutics (FOLD) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - April 25 at 12:26 AM |
 | Technical Perspectives on Biotech Stocks -- Alnylam Pharma, Amgen, Amicus Therapeutics, and Ampio Pharma
www.prnewswire.com - April 20 at 8:01 AM |
 | Implied Volatility Surging for Amicus Therapeutics (FOLD) Stock Options
www.zacks.com - April 20 at 8:01 AM |
| Amicus Therapeutics (FOLD) Insider Hung Do Sells 50,000 Shares
www.americanbankingnews.com - April 19 at 7:34 PM |
| Amicus Therapeutics (FOLD) Director Sells $72,050.00 in Stock
www.americanbankingnews.com - April 18 at 7:49 PM |
| Jay Barth Sells 5,000 Shares of Amicus Therapeutics (FOLD) Stock
www.americanbankingnews.com - April 16 at 7:14 PM |
| Portfolio Review: Continued Market Outperformance In Q1 2018
seekingalpha.com - April 15 at 8:43 AM |
| Amicus Therapeutics (FOLD) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 15 at 3:25 AM |
| $16.78 Million in Sales Expected for Amicus Therapeutics (FOLD) This Quarter
www.americanbankingnews.com - April 14 at 4:39 AM |
| Amicus Therapeutics (FOLD) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - April 14 at 12:49 AM |
| Amicus Therapeutics (FOLD) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - April 13 at 11:05 AM |
| Zacks: Analysts Expect Amicus Therapeutics (FOLD) Will Post Earnings of -$0.36 Per Share
www.americanbankingnews.com - April 12 at 5:23 AM |
| Amicus Therapeutics Sees Unusually High Options Volume (FOLD)
www.americanbankingnews.com - April 11 at 7:06 AM |
| Amicus Therapeutics (FOLD) PT Raised to $17.50
www.americanbankingnews.com - April 10 at 11:38 PM |
| Amicus Therapeutics (FOLD) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 7 at 3:52 PM |
Amicus Therapeutics (NASDAQ:FOLD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Amicus Therapeutics (NASDAQ:FOLD) Income Statement, Balance Sheet and Cash Flow Statement
Amicus Therapeutics (NASDAQ FOLD) Stock Chart for Saturday, May, 26, 2018
Loading chart…
